3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
16
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Small Cell Lung Carcinoma
3
Carcinoma
3
Urothelial Cancer
2
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Endometrial Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Recurrence
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
1
Non Small Cell Lung Cancer NSCLC
1
Neurocytoma
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Metastatic Urothelial Cancer
1
Mesothelioma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Ganglioneuroma
1
Ganglioglioma
1
Interventions
enfortumab vedotin
2
pembrolizumab
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Urethral Neoplasms
×
Carboplatin
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA